
Jan 22 (Reuters) - Valneva SE VLS.PA:
VALNEVA REPORTS POSITIVE PHASE 2 RESULTS IN CHILDREN FOR ITS CHIKUNGUNYA VACCINE AND ANNOUNCES PHASE 3 DOSE DECISION
VALNEVA SE - TRIAL SHOWS VACCINE WELL TOLERATED BY CHILDREN AGED 1-11 YEARS
VALNEVA SE - TO INITIATE PIVOTAL PHASE 3 STUDY IN CHILDREN IN Q4 2025
VALNEVA SE - EXPECTS MARKETING APPROVAL IN BRAZIL AND UK IN Q1
((Reuters.Briefs@thomsonreuters.com;;))